The Food and Drug Administration (FDA) may approve the first long-acting therapy for HIV pre-exposure prophylaxis (PrEP) within the next few months. On Tuesday, the pharmaceutical company ViiV Healthcare announced that the FDA has accepted and granted priority review for a new drug application (NDA) for cabotegravir, an injectable form of PrEP administered every two months. According to UNAIDS, new HIV infections worldwide declined by 30% from 2010. Furthermore, after a period of general stability, new HIV infections declined by 8% from 2015 t0 2019. However, new HIV infections continue in certain regions and populations.

Source: MetroXpress September 30, 2021 16:52 UTC